<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula</h2>
    <div class="badge">2025-09-08T10:45:00+00:00</div>
    <ul>
      <li>Pfizer Disclosure Notice The information contained in this release is as of September 8, 2025.</li>
<li>at 1-800-438-1985 or www.pfizersafetyreporting.com.</li>
<li>For 175 years, we have worked to make a difference for all who rely on us.</li>
<li>INDICATION AND IMPORTANT SAFETY INFORMATION INDICATION COMIRNATY (COVID-19 VACCINE, mRNA) is a vaccine to protect against coronavirus disease 2019 (COVID-19).</li>
<li>You should review the risks and uncertainties described under the heading &quot;Risk Factors&quot; in BioNTech&#x27;s Report on Form 6-K for the period ended June 30, 2025, and in subsequent filings made by BioNTech with the SEC, which</li>
<li>Prior to receiving the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula, all participants had received the KP.2-adapted COVID-19 vaccine at least six months prior to enrollment and had not received any other COVID-19 va</li>
<li>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections there</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula\n• Pfizer Disclosure Notice The information contained in this release is as of September 8, 2025.\n• at 1-800-438-1985 or www.pfizersafetyreporting.com.\n• For 175 years, we have worked to make a difference for all who rely on us.\n• INDICATION AND IMPORTANT SAFETY INFORMATION INDICATION COMIRNATY (COVID-19 VACCINE, mRNA) is a vaccine to protect against coronavirus disease 2019 (COVID-19).\n• You should review the risks and uncertainties described under the heading &quot;Risk Factors&quot; in BioNTech&#x27;s Report on Form 6-K for the period ended June 30, 2025, and in subsequent filings made by BioNTech with the SEC, which\n• Prior to receiving the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula, all participants had received the KP.2-adapted COVID-19 vaccine at least six months prior to enrollment and had not received any other COVID-19 va\n• A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections there" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/pfizer-biontech-announce-topline-data-104500046.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>